Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01253213

BR55 in Prostate Cancer: an Exploratory Clinical Trial

Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2

Sponsor: Bracco Diagnostics, Inc

Conditions Prostate Cancer

Interventions BR55

Updated 7 times since 2017 Last updated: Jul 31, 2023 Started: Jul 31, 2010 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01253213, this EARLY_PHASE1 trial focuses on Prostate Cancer and remains completed. Sponsored by Bracco Diagnostics, Inc, it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Sep 2023 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Sep 2023 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bracco Diagnostics, Inc
Bracco Imaging S.p.A.

Data source: Bracco Diagnostics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands